Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an all-cash transaction valued at$8bn, boosting its oncology pipeline. The acquisition, which has received unanimous support from both companies' boards of directors, is expected to advance Genmab's transition to a fully owned business model. A subsidiary of Genmab will initiate a tender offer to acquire 100% of the common shares of Merus, with the deal projected to close early in the firs ...